These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24045181)

  • 1. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
    Ye Q; Song DG; Poussin M; Yamamoto T; Best A; Li C; Coukos G; Powell DJ
    Clin Cancer Res; 2014 Jan; 20(1):44-55. PubMed ID: 24045181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
    Eiva MA; Omran DK; Chacon JA; Powell DJ
    Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Tubridy EA; Eiva MA; Liu F; Omran DK; Gysler S; Brown EG; Roy AG; Zeng Y; Oh J; Cao Q; Gitto SB; Powell DJ
    Gynecol Oncol; 2024 May; 184():74-82. PubMed ID: 38290413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
    Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
    J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 10. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1
    Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; Muruzabal JC; Alcaide J; Guillen-Grima F; Minguez JA; Amores-Tirado J; Gonzalez-Martin A; Sarobe P; Lasarte JJ; Ponz-Sarvise M; De Andrea CE; Hervas-Stubbs S
    Br J Cancer; 2021 Mar; 124(6):1138-1149. PubMed ID: 33402737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.
    Goldstein MJ; Kohrt HE; Houot R; Varghese B; Lin JT; Swanson E; Levy R
    Cancer Res; 2012 Mar; 72(5):1239-47. PubMed ID: 22232735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert.
    Zhu Y; Chen L
    Clin Cancer Res; 2014 Jan; 20(1):3-5. PubMed ID: 24166912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
    Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Identification of the Tumor-Specific Reactive TIL Repertoire
    Draghi A; Chamberlain CA; Khan S; Papp K; Lauss M; Soraggi S; Radic HD; Presti M; Harbst K; Gokuldass A; Kverneland A; Nielsen M; Westergaard MCW; Andersen MH; Csabai I; Jönsson G; Szallasi Z; Svane IM; Donia M
    Front Immunol; 2021; 12():705422. PubMed ID: 34707600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
    Turcotte S; Gros A; Hogan K; Tran E; Hinrichs CS; Wunderlich JR; Dudley ME; Rosenberg SA
    J Immunol; 2013 Sep; 191(5):2217-25. PubMed ID: 23904171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
    Inozume T; Hanada K; Wang QJ; Ahmadzadeh M; Wunderlich JR; Rosenberg SA; Yang JC
    J Immunother; 2010; 33(9):956-64. PubMed ID: 20948441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.